Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Clinical Impact, Costs, and Cost-Effectiveness of Expanded SARS-CoV-2 Testing in Massachusetts

View ORCID ProfileAnne M. Neilan, Elena Losina, Audrey C. Bangs, Clare Flanagan, Christopher Panella, G. Ege Eskibozkurt, Amir Mohareb, Emily P. Hyle, Justine A. Scott, Milton C. Weinstein, Mark J. Siedner, Krishna P. Reddy, Guy Harling, Kenneth A. Freedberg, Fatma M. Shebl, Pooyan Kazemian, Andrea L. Ciaranello
doi: https://doi.org/10.1101/2020.07.23.20160820
Anne M. Neilan
1Division of General Academic Pediatrics, Department of Pediatrics, Massachusetts General Hospital, Boston, MA
2Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA
3Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA
4Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anne M. Neilan
  • For correspondence: aneilan@mgh.harvard.edu
Elena Losina
4Harvard Medical School, Boston, MA
5Orthopedic and Arthritis Center for Outcomes Research (OrACORe), Department of Orthopedic Surgery, Brigham and Women’s Hospital, Boston, MA
6Policy and Innovation eValuation in Orthopedic Treatments (PIVOT) Center, Department of Orthopedic Surgery, Brigham and Women’s Hospital, Boston, MA
7Department of Biostatistics, Boston University School of Public Health, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Audrey C. Bangs
3Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clare Flanagan
3Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Panella
3Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Ege Eskibozkurt
3Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amir Mohareb
2Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA
3Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA
4Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily P. Hyle
2Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA
3Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA
4Harvard Medical School, Boston, MA
8Harvard University Center for AIDS Research, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justine A. Scott
3Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Milton C. Weinstein
9Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J. Siedner
2Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA
3Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA
4Harvard Medical School, Boston, MA
10Africa Health Research Institute, KwaZulu-Natal, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krishna P. Reddy
3Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA
4Harvard Medical School, Boston, MA
11Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guy Harling
10Africa Health Research Institute, KwaZulu-Natal, South Africa
12Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA
13Institute for Global Health, University College London, London, UK
14MRC/Wits Rural Public Health & Health Transitions Research Unit (Agincourt), University of the Witwatersrand, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth A. Freedberg
2Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA
3Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA
4Harvard Medical School, Boston, MA
9Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA
15Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fatma M. Shebl
3Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA
4Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pooyan Kazemian
3Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA
4Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea L. Ciaranello
2Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA
3Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA
4Harvard Medical School, Boston, MA
8Harvard University Center for AIDS Research, Cambridge, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background We projected the clinical and economic impact of alternative testing strategies on COVID-19 incidence and mortality in Massachusetts using a microsimulation model.

Methods We compared five testing strategies: 1) PCR-severe-only: PCR testing only patients with severe/critical symptoms; 2) Self-screen: PCR-severe-only plus self-assessment of COVID-19-consistent symptoms with self-isolation if positive; 3) PCR-any-symptom: PCR for any COVID-19-consistent symptoms with self-isolation if positive; 4) PCR-all: PCR-any-symptom and one-time PCR for the entire population; and, 5) PCR-all-repeat: PCR-all with monthly re-testing. We examined effective reproduction numbers (Re, 0.9-2.0) at which policy conclusions would change. We used published data on disease progression and mortality, transmission, PCR sensitivity/specificity (70/100%) and costs. Model-projected outcomes included infections, deaths, tests performed, hospital-days, and costs over 180-days, as well as incremental cost-effectiveness ratios (ICERs, $/quality-adjusted life-year [QALY]).

Results In all scenarios, PCR-all-repeat would lead to the best clinical outcomes and PCR-severe-only would lead to the worst; at Re 0.9, PCR-all-repeat vs. PCR-severe-only resulted in a 63% reduction in infections and a 44% reduction in deaths, but required >65-fold more tests/day with 4-fold higher costs. PCR-all-repeat had an ICER <$100,000/QALY only when Re ≥1.8. At all Re values, PCR-any-symptom was cost-saving compared to other strategies.

Conclusions Testing people with any COVID-19-consistent symptoms would be cost-saving compared to restricting testing to only those with symptoms severe enough to warrant hospital care. Expanding PCR testing to asymptomatic people would decrease infections, deaths, and hospitalizations. Universal screening would be cost-effective when paired with monthly retesting in settings where the COVID-19 pandemic is surging.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the Eunice Kennedy Shriver National Institute for Child Health and Human Development [K08 HD094638 to AMN], the National Institute of Allergy and Infectious Disease at the National Institutes of Health [T32 AI007433 to AM], and the Wellcome Trust [210479/Z/18/Z to GH]. The content is solely the responsibility of the authors, and the study's findings and conclusions do not necessarily represent the official views of the National Institutes of Health, the Wellcome Trust, or other funders.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Approved by the Partners Human Research Committee under Protocol 2020P000967 All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • MAIN POINT Screening asymptomatic people for COVID-19, when paired with self-isolation, would decrease infections and deaths. Universal screening with monthly retesting would be cost-effective at effective reproduction numbers (Re) > 1.8; at lower Re, restricting testing to those with any symptoms would be economically preferred.

Data Availability

The analysis was conducted from the data presenting in the manuscript and supplemental appendix.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 24, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Impact, Costs, and Cost-Effectiveness of Expanded SARS-CoV-2 Testing in Massachusetts
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clinical Impact, Costs, and Cost-Effectiveness of Expanded SARS-CoV-2 Testing in Massachusetts
Anne M. Neilan, Elena Losina, Audrey C. Bangs, Clare Flanagan, Christopher Panella, G. Ege Eskibozkurt, Amir Mohareb, Emily P. Hyle, Justine A. Scott, Milton C. Weinstein, Mark J. Siedner, Krishna P. Reddy, Guy Harling, Kenneth A. Freedberg, Fatma M. Shebl, Pooyan Kazemian, Andrea L. Ciaranello
medRxiv 2020.07.23.20160820; doi: https://doi.org/10.1101/2020.07.23.20160820
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Clinical Impact, Costs, and Cost-Effectiveness of Expanded SARS-CoV-2 Testing in Massachusetts
Anne M. Neilan, Elena Losina, Audrey C. Bangs, Clare Flanagan, Christopher Panella, G. Ege Eskibozkurt, Amir Mohareb, Emily P. Hyle, Justine A. Scott, Milton C. Weinstein, Mark J. Siedner, Krishna P. Reddy, Guy Harling, Kenneth A. Freedberg, Fatma M. Shebl, Pooyan Kazemian, Andrea L. Ciaranello
medRxiv 2020.07.23.20160820; doi: https://doi.org/10.1101/2020.07.23.20160820

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (170)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8790)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1864)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (492)
  • Hematology (207)
  • HIV/AIDS (395)
  • Infectious Diseases (except HIV/AIDS) (10567)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1756)
  • Nursing (103)
  • Nutrition (266)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (965)
  • Ophthalmology (283)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (264)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (219)
  • Psychiatry and Clinical Psychology (1845)
  • Public and Global Health (3986)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (535)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)